Aclarion, Inc. (NASDAQ:ACON) Short Interest Update

Aclarion, Inc. (NASDAQ:ACON) was the recipient of a large increase in short interest during the month of January. As of January 30th, there was short interest totaling 178,163 shares, an increase of 19.8% from the January 15th total of 148,674 shares. Currently, 21.0% of the company’s shares are sold short. Based on an average daily trading volume, of 159,610 shares, the days-to-cover ratio is presently 1.1 days. Based on an average daily trading volume, of 159,610 shares, the days-to-cover ratio is presently 1.1 days. Currently, 21.0% of the company’s shares are sold short.

Aclarion Stock Down 3.9%

Shares of ACON stock opened at $2.49 on Thursday. The business’s fifty day moving average is $4.35 and its 200 day moving average is $6.30. The stock has a market cap of $2.12 million, a price-to-earnings ratio of -0.17 and a beta of 1.44. Aclarion has a twelve month low of $2.34 and a twelve month high of $229.50.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Aclarion in a report on Wednesday, January 21st. Wall Street Zen cut shares of Aclarion from a “hold” rating to a “sell” rating in a research report on Saturday, February 14th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of “Sell”.

Aclarion Company Profile

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc and changed its name to Aclarion, Inc in December 2021.